Behandeling voor endocarditis afronden met orale antibiotica?

Research output: Contribution to journalArticleProfessional

Abstract

The recently published POET trial breaks with the established paradigm of long-term, high-dose intravenous antibiotics for all patients with endocarditis. The study involved 400 Danish patients who had endocarditis caused by Gram-positive micro-organisms and who had a favourable response to initial intravenous therapy. The IV to oral switch appeared to be non-inferior to continuing intravenous treatment. From the perspective of antibiotic stewardship, this is a step forward because a shorter period of intravenous therapy reduces catheter-associated complications. However, treating clinicians should realise that the study had strict inclusion criteria and that its results apply to selected, low-risk patients only.
Original languageDutch
JournalNederlands Tijdschrift voor Geneeskunde
Volume163
Publication statusPublished - 2019

Cite this

@article{9882a8b6e6604964bf8bee8340d4399c,
title = "Behandeling voor endocarditis afronden met orale antibiotica?",
abstract = "The recently published POET trial breaks with the established paradigm of long-term, high-dose intravenous antibiotics for all patients with endocarditis. The study involved 400 Danish patients who had endocarditis caused by Gram-positive micro-organisms and who had a favourable response to initial intravenous therapy. The IV to oral switch appeared to be non-inferior to continuing intravenous treatment. From the perspective of antibiotic stewardship, this is a step forward because a shorter period of intravenous therapy reduces catheter-associated complications. However, treating clinicians should realise that the study had strict inclusion criteria and that its results apply to selected, low-risk patients only.",
author = "Sigaloff, {Kim C. E.}",
year = "2019",
language = "Dutch",
volume = "163",
journal = "Nederlands Tijdschrift voor Geneeskunde",
issn = "0028-2162",
publisher = "Bohn Stafleu van Loghum",

}

Behandeling voor endocarditis afronden met orale antibiotica? / Sigaloff, Kim C. E.

In: Nederlands Tijdschrift voor Geneeskunde, Vol. 163, 2019.

Research output: Contribution to journalArticleProfessional

TY - JOUR

T1 - Behandeling voor endocarditis afronden met orale antibiotica?

AU - Sigaloff, Kim C. E.

PY - 2019

Y1 - 2019

N2 - The recently published POET trial breaks with the established paradigm of long-term, high-dose intravenous antibiotics for all patients with endocarditis. The study involved 400 Danish patients who had endocarditis caused by Gram-positive micro-organisms and who had a favourable response to initial intravenous therapy. The IV to oral switch appeared to be non-inferior to continuing intravenous treatment. From the perspective of antibiotic stewardship, this is a step forward because a shorter period of intravenous therapy reduces catheter-associated complications. However, treating clinicians should realise that the study had strict inclusion criteria and that its results apply to selected, low-risk patients only.

AB - The recently published POET trial breaks with the established paradigm of long-term, high-dose intravenous antibiotics for all patients with endocarditis. The study involved 400 Danish patients who had endocarditis caused by Gram-positive micro-organisms and who had a favourable response to initial intravenous therapy. The IV to oral switch appeared to be non-inferior to continuing intravenous treatment. From the perspective of antibiotic stewardship, this is a step forward because a shorter period of intravenous therapy reduces catheter-associated complications. However, treating clinicians should realise that the study had strict inclusion criteria and that its results apply to selected, low-risk patients only.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85065575956&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/31050269

M3 - Article

VL - 163

JO - Nederlands Tijdschrift voor Geneeskunde

JF - Nederlands Tijdschrift voor Geneeskunde

SN - 0028-2162

ER -